Back to Search
Start Over
Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient [version 3; peer review: 1 approved, 1 approved with reservations]
- Source :
- F1000Research. 10:761
- Publication Year :
- 2022
- Publisher :
- London, UK: F1000 Research Limited, 2022.
-
Abstract
- Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the revealing manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.
Details
- ISSN :
- 20461402
- Volume :
- 10
- Database :
- F1000Research
- Journal :
- F1000Research
- Notes :
- Revised Amendments from Version 2 I have replaced the word "primary" by revealing in the discussion section. I have discussed the significance of the positivity of anti-CCP antibodies in this observation., , [version 3; peer review: 1 approved, 1 approved with reservations]
- Publication Type :
- Academic Journal
- Accession number :
- edsfor.10.12688.f1000research.55189.3
- Document Type :
- case-report
- Full Text :
- https://doi.org/10.12688/f1000research.55189.3